📊 ATRA Key Takeaways
Is Atara Biotherapeutics, Inc. (ATRA) a Good Investment?
Atara Biotherapeutics faces existential financial distress with negative shareholders' equity of -$37.3M, minimal revenue of $516K with zero growth, and quarterly operating cash burn of -$3.1M. With only $8.4M cash on hand and a negative operating margin of -652.9%, the company has approximately 2-3 quarters of runway and requires urgent capital infusion or transformational revenue generation to avoid insolvency.
Despite reported operating and net profitability, the company’s earnings quality appears weak because cash generation is deeply negative, with operating cash flow and free cash flow both at -$50.94M. The balance sheet is highly stressed, with only $8.48M of cash, a sub-1.0 current ratio, and negative stockholders’ equity, which materially raises financing and going-concern risk unless fundamentals improve quickly.
Atara Biotherapeutics, Inc. Key Strengths (ATRA)
- Maintains $8.4M cash position providing near-term liquidity buffer
- Current ratio of 2.16x indicates short-term current assets exceed current liabilities by reasonable margin
- EPS improvement of 122.5% YoY suggests potential operational adjustments, though from severely depressed base
- Reported operating margin of 29.7% and net margin of 27.1% indicate headline profitability in the latest period
- Revenue base of $120.77M provides some operating scale relative to the company’s asset base
- Interest coverage of 9.5x suggests current earnings are presently sufficient to cover interest expense
ATRA Stock Risks: Atara Biotherapeutics, Inc. Investment Risks
- Negative shareholders' equity of -$37.3M represents technical insolvency with total liabilities ($57.3M) exceeding total assets ($20.0M)
- Severe cash burn of -$3.1M per quarter against only $8.4M cash reserves creates 2-3 quarter survival horizon without capital injection
- Revenue stagnation at $516K with 0% YoY growth and massive operating losses (-$3.4M) indicate company has not achieved commercial viability
- Operating cash flow and free cash flow are strongly negative, indicating poor earnings quality and cash burn
- Negative stockholders’ equity and total liabilities far above total assets point to severe balance-sheet weakness
- Current and quick ratios of 0.82x imply constrained near-term liquidity and potential need for external capital
Key Metrics to Watch
- Cash burn rate and remaining runway - critical for assessing near-term solvency risk
- Quarterly revenue trends and evidence of commercial traction - essential for long-term viability
- Capital raise announcements or partnering deals - necessary to extend operating runway and fund development
- Operating cash flow/free cash flow trend versus reported net income
- Cash balance and current ratio, including any changes in liabilities or equity restoration
Atara Biotherapeutics, Inc. (ATRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.16x current ratio provides a solid financial cushion.
ATRA Profit Margin, ROE & Profitability Analysis
ATRA vs Healthcare Sector: How Atara Biotherapeutics, Inc. Compares
How Atara Biotherapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Atara Biotherapeutics, Inc. Stock Overvalued? ATRA Valuation Analysis 2026
Based on fundamental analysis, Atara Biotherapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Atara Biotherapeutics, Inc. Balance Sheet: ATRA Debt, Cash & Liquidity
ATRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Atara Biotherapeutics, Inc.'s revenue has grown significantly by 103% over the 5-year period, indicating strong business expansion. The most recent EPS of $-11.41 indicates the company is currently unprofitable.
ATRA Revenue Growth, EPS Growth & YoY Performance
ATRA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $2.1M | -$19.0M | $-2.93 |
| Q2 2024 | $957.0K | -$19.0M | $-3.10 |
| Q1 2024 | $1.2M | -$31.8M | $-0.23 |
| Q3 2023 | $2.1M | $18.5M | $-0.66 |
| Q2 2023 | $957.0K | $18.5M | $0.18 |
| Q1 2023 | $1.2M | -$74.8M | $-0.72 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Atara Biotherapeutics, Inc. Dividends, Buybacks & Capital Allocation
ATRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Atara Biotherapeutics, Inc. (CIK: 0001604464)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ATRA
What is the AI rating for ATRA?
Atara Biotherapeutics, Inc. (ATRA) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATRA's key strengths?
Claude: Maintains $8.4M cash position providing near-term liquidity buffer. Current ratio of 2.16x indicates short-term current assets exceed current liabilities by reasonable margin. ChatGPT: Reported operating margin of 29.7% and net margin of 27.1% indicate headline profitability in the latest period. Revenue base of $120.77M provides some operating scale relative to the company’s asset base.
What are the risks of investing in ATRA?
Claude: Negative shareholders' equity of -$37.3M represents technical insolvency with total liabilities ($57.3M) exceeding total assets ($20.0M). Severe cash burn of -$3.1M per quarter against only $8.4M cash reserves creates 2-3 quarter survival horizon without capital injection. ChatGPT: Operating cash flow and free cash flow are strongly negative, indicating poor earnings quality and cash burn. Negative stockholders’ equity and total liabilities far above total assets point to severe balance-sheet weakness.
What is ATRA's revenue and growth?
Atara Biotherapeutics, Inc. reported revenue of $516.0K.
Does ATRA pay dividends?
Atara Biotherapeutics, Inc. does not currently pay dividends.
Where can I find ATRA SEC filings?
Official SEC filings for Atara Biotherapeutics, Inc. (CIK: 0001604464) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATRA's EPS?
Atara Biotherapeutics, Inc. has a diluted EPS of $-0.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ATRA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Atara Biotherapeutics, Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ATRA stock overvalued or undervalued?
Valuation metrics for ATRA: ROE of N/A (sector avg: 15%), net margin of -803.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ATRA's AI grade for 2026?
Our dual AI analysis gives Atara Biotherapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ATRA's free cash flow?
Atara Biotherapeutics, Inc.'s operating cash flow is $-3.1M, with capital expenditures of $0.0. FCF margin is -595.5%.
How does ATRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -803.3% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.16 (avg: 2).